Highest-materiality recent filing
Lite Strategy reports $0.7M yield from LTC covered calls, repurchases 1.6M shares
Generated $0.7M net proceeds from covered call program on LTC holdings since Oct 2025.
Lite Strategy authorizes $25M share repurchase; director Reynolds resigns
Board authorized $25M share repurchase program, effective immediately, through open market or negotiated transactions.
MEI Pharma rebrands as Lite Strategy, Inc., adopts digital asset treasury with LTC
Company changes name to Lite Strategy, Inc.; NASDAQ ticker changes from MEIP to LITS effective Sep 11, 2025.
Acquired 929,548 LTC tokens at avg price $107.58; LTC treasury valued at ~$110.4M as of Aug 4, 2025.
MEI Pharma Raises $100M in PIPE to Launch Litecoin Treasury Strategy; Charlie Lee Appointed to Board
Gross proceeds of ~$100M from sale of 29.2M shares/pre-funded warrants at $3.42 per share.
MEI Pharma reports $23.7M cash, no debt, continues strategic alternatives review
Cash and cash equivalents $23.7M as of Dec 31, 2024; no outstanding debt.
MEI Pharma sells rights to ME-344 to Aardvark Therapeutics for up to $62.5M milestones
Closed on Oct 22, 2024: sold ME-344 assets (IP, contracts, technology) to Aardvark Therapeutics for $0.5M upfront plus $55K reimbursement.
MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives
Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.
CEO and CMO depart; MEI Pharma evaluates wind-down; CFO becomes Acting CEO
CEO David M. Urso and CMO Richard G. Ghalie depart effective Aug 1, 2024; eligible for severance (12 mo salary, COBRA, prorated bonus, accelerated vesting).
MEI Pharma halts voruciclib clinical development, begins strategic alternatives review
Board unanimously decided to evaluate strategic alternatives including potential transactions or orderly wind-down.
MEI Pharma halts voruciclib, cuts workforce, CEO/CMO depart, evaluates wind-down
Board unanimously begins evaluation of strategic alternatives including transactions or orderly wind-down.
MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium
CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.
MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program
Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.
Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.
MEI Pharma Q1 net income $56.4M on deferred revenue; clinical trials on track
Net income $56.4M ($8.46 EPS) vs prior-year net loss $16.6M; revenue $65.3M from Kyowa Kirin termination.
Immediate dividend of $1.75 per share paid to all stockholders; potential additional $9.33M return contingent on ME-344 trial results or Board decision.
MEI Pharma adopts poison pill after Anson/Cable Car accumulate ~19.9% stake
Rights plan triggers at 20% ownership; expires September 30, 2024.
MEI Pharma FY2023 net loss $31.8M; cash $100.7M; merger fails, CEO changed
Net loss $31.8M ($4.78/share) vs $54.5M ($8.75/share) prior year; revenue $48.8M, up from $40.7M.
MEI Pharma promotes Justin File to CFO; Brian Drazba departs without cause
Justin J. File appointed CFO and Corporate Secretary effective August 1, 2023.
MEI Pharma terminates merger with Infinity after stockholder vote fails
Stockholders voted against merger: 47.86% for, 51.44% against; turnout 59.70% of outstanding shares.
Mutually terminated License, Development and Commercialization Agreement with Kyowa Kirin for ME-401 effective July 14, 2023.
MEI Pharma rejects activist consent solicitation to remove board without cause under Delaware law
Anson Advisors and Cable Car Capital launched consent solicitation on July 17, 2023 to remove all directors without cause and repeal recent bylaw amendments.
MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 23 special meeting
MEI mailed letter to shareholders on July 17, 2023, pleading vote FOR the Infinity (INFI) merger at the July 23 special meeting.
MEI Pharma postpones special meeting on Infinity merger to July 23, 2023
Special meeting postponed from original date to July 23, 2023 at 10:00 a.m. ET; may be further adjourned.
Glass Lewis joins ISS in recommending MEI Pharma shareholders vote FOR Infinity merger
Both ISS and Glass Lewis recommend shareholders vote FOR the Infinity merger.
ISS recommends MEI Pharma shareholders vote FOR merger with Infinity Pharma
Independent proxy advisory ISS recommends voting FOR the Infinity merger at July 14 special meeting.
David M. Urso, the Company’s President and Chief Executive Officer, and Richard G. Ghalie, M.D., its Chief Medical Officer, will be leaving the Company effective August 1, 2024.
David M. Urso, the Company’s President and Chief Executive Officer, and Richard G. Ghalie, M.D., its Chief Medical Officer, will be leaving the Company effective August 1, 2024.
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
The Board has appointed Frederick W. Driscoll as Chairperson of the Company.
The Board has appointed Justin J. File, age 53, currently the Company’s Chief Financial Officer and Secretary, to serve in the additional capacity of Acting Chief Executive Officer (“Acting CEO”), effective as of August 1, 2024.
Charles V. Baltic III, the current Chairperson of the Board, will also step down from the Board effective immediately.
Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board
Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board
Mr. Steven Wood, as mutually agreed upon by the Company and Anson Funds and Cable Car, has been appointed to the Board as an additional MEI stockholder representative designated by the Board.
the Company has appointed two directors designated by Anson Funds and Cable Car: Mr. James Flynn and Mr. Taheer Datoo.
Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board
Max materiality 0.95 · Median 0.60 · Most common event other_material